Voting is over

Teva Pharmaceuticals (TEVA) Will Not Fall Below $30
7 july

Teva Pharmaceuticals (TEVA) recovered in the last month as biotech stocks found buyers. For July, the selling pressure from technology, led by Apple's steady fall and Tesla's big correction - thank Goldman Sachs - could hurt TEVA stock.

$TEVA, TEVA PHARMACEUTICAL INDUSTRIES LIMITED AMERICAN DEPOSITARY SHARES / H1


Still, Teva has strong upside and new leadership that will consolidate the generics unit.

TEVA will not fall below $30.

Agree or disagree?

Login to vote! Sign in via Stocktwits.

"Like" this post.

Related: ENDP is deep value. VRX is treading towards the $19 - $20 PT (price target). Allergan (AGN) shed its generics unit. 

Answered:
10 people

Teva Pharmaceuticals (TEVA) Will Not Fall Below $30

Voting is over
Waiting for
the right answer
Agreed
6 people
Disagreed
4 people